文献
J-GLOBAL ID:202202279573017172
整理番号:22A1174139
フィンゴリモドの中止後の多発性硬化症再発【JST・京大機械翻訳】
Multiple Sclerosis Relapses Following Cessation of Fingolimod
著者 (31件):
Malpas Charles B.
(Department of Medicine, CORe, University of Melbourne, Melbourne, VIC, Australia)
,
Malpas Charles B.
(Department of Neurology, Royal Melbourne Hospital, Melbourne MS Centre, Melbourne, VIC, Australia)
,
Roos Izanne
(Department of Medicine, CORe, University of Melbourne, Melbourne, VIC, Australia)
,
Roos Izanne
(Department of Neurology, Royal Melbourne Hospital, Melbourne MS Centre, Melbourne, VIC, Australia)
,
Sharmin Sifat
(Department of Medicine, CORe, University of Melbourne, Melbourne, VIC, Australia)
,
Sharmin Sifat
(Department of Neurology, Royal Melbourne Hospital, Melbourne MS Centre, Melbourne, VIC, Australia)
,
Buzzard Katherine
(Box Hill Hospital, Melbourne, VIC, Australia)
,
Buzzard Katherine
(Monash University, Melbourne, VIC, Australia)
,
Buzzard Katherine
(Royal Melbourne Hospital, Melbourne MS Centre, Melbourne, VIC, Australia)
,
Skibina Olga
(Box Hill Hospital, Melbourne, VIC, Australia)
,
Skibina Olga
(Monash University, Melbourne, VIC, Australia)
,
Skibina Olga
(The Alfred Hospital, Melbourne, VIC, Australia)
,
Butzkueven Helmut
(Central Clinical School, Monash University, Melbourne, VIC, Australia)
,
Butzkueven Helmut
(Department of Neurology, The Alfred Hospital, Melbourne, VIC, Australia)
,
Butzkueven Helmut
(Department of Neurology, Box Hill Hospital, Monash University, Melbourne, VIC, Australia)
,
Kappos Ludwig
(Departments of Medicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Basel, Switzerland)
,
Patti Francesco
(GF Ingrassia Department, University of Catania, Catania, Italy)
,
Patti Francesco
(Policlinico G Rodolico, Catania, Italy)
,
Alroughani Raed
(Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait)
,
Horakova Dana
(Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic)
,
Havrdova Eva Kubala
(Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic)
,
Izquierdo Guillermo
(Hospital Universitario Virgen Macarena, Sevilla, Spain)
,
Eichau Sara
(Hospital Universitario Virgen Macarena, Sevilla, Spain)
,
Hodgkinson Suzanne
(Liverpool Hospital, Sydney, NSW, Australia)
,
Grammond Pierre
(CISSS ChaudiEEre-Appalache, Levis, QC, Canada)
,
Lechner-Scott Jeannette
(School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia)
,
Lechner-Scott Jeannette
(Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia)
,
Kalincik Tomas
(Department of Medicine, CORe, University of Melbourne, Melbourne, VIC, Australia)
,
Kalincik Tomas
(Department of Neurology, Royal Melbourne Hospital, Melbourne MS Centre, Melbourne, VIC, Australia)
,
Kalincik Tomas
(L4 Centre, Melbourne Brain Centre at Royal Melbourne Hospital, Parkville, VIC, Australia)
,
the MSBase Study Group
資料名:
Clinical Drug Investigation
(Clinical Drug Investigation)
巻:
42
号:
4
ページ:
355-364
発行年:
2022年
JST資料番号:
T0873A
ISSN:
1173-2563
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
ドイツ (DEU)
言語:
英語 (EN)